Molecular Pharmacology (USA) Ltd
Molecular Pharmacology (USA), Ltd., a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States. The company, through its subsidiary, Molecular Pharmacology Pty. Ltd., develops analgesic and anti-inflammatory molecule, known as Tripeptofen for the treatment of common every-day pain. Its products are available in v… Read more
Molecular Pharmacology (USA) Ltd (MLPH) - Net Assets
Latest net assets as of September 2014: $-2.10 Million USD
Based on the latest financial reports, Molecular Pharmacology (USA) Ltd (MLPH) has net assets worth $-2.10 Million USD as of September 2014.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.84K) and total liabilities ($2.11 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-2.10 Million |
| % of Total Assets | -23732.18% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Molecular Pharmacology (USA) Ltd - Net Assets Trend (2004–2014)
This chart illustrates how Molecular Pharmacology (USA) Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Molecular Pharmacology (USA) Ltd (2004–2014)
The table below shows the annual net assets of Molecular Pharmacology (USA) Ltd from 2004 to 2014.
| Year | Net Assets | Change |
|---|---|---|
| 2014-06-30 | $-2.23 Million | -8.71% |
| 2013-06-30 | $-2.05 Million | +1.25% |
| 2012-06-30 | $-2.08 Million | -5.75% |
| 2011-06-30 | $-1.97 Million | -32.27% |
| 2010-06-30 | $-1.49 Million | -15.16% |
| 2009-06-30 | $-1.29 Million | +1.56% |
| 2007-06-30 | $-1.31 Million | -354.87% |
| 2006-06-30 | $-288.36K | -1548.87% |
| 2004-06-30 | $19.90K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Molecular Pharmacology (USA) Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 210933200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2014)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $111.55K | % |
| Other Comprehensive Income | $-272.24K | % |
| Other Components | $106.71K | % |
| Total Equity | $-2.23 Million | 100.00% |
Molecular Pharmacology (USA) Ltd Competitors by Market Cap
The table below lists competitors of Molecular Pharmacology (USA) Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nyle International Corp
OTCGREY:NYLE
|
$3.77 |
|
AMALGAMATED REGIONAL TRADING (ART) HOLDINGS LIMITED
XZIM:ARTD
|
$3.78 |
|
EUROAFRICA DIGITAL VENT.
F:9BX
|
$3.79 |
|
Worldwide Holdings Corp
PINK:WWDH
|
$3.80 |
|
Hutn Inc
PINK:HUTN
|
$3.72 |
|
Puissant Industries Inc
PINK:PSSS
|
$3.71 |
|
Hop-On Inc
PINK:HPNN
|
$3.71 |
|
Itonis Inc
PINK:ITNS
|
$3.69 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Molecular Pharmacology (USA) Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2013 to 2014, total equity changed from -2,053,873 to -2,232,854, a change of -178,981.
- Net loss of 116,928 reduced equity.
- Other comprehensive income decreased equity by 62,053.
- Other factors decreased equity by 0.
Equity Change Factors (2013 to 2014)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-116.93K | -5.24% |
| Other Comprehensive Income | $-62.05K | -2.78% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Molecular Pharmacology (USA) Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-06-30 | $0.00 | $0.00 | x |
| 2006-06-30 | $-0.01 | $0.00 | x |
| 2007-06-30 | $-0.01 | $0.00 | x |
| 2009-06-30 | $-0.01 | $0.00 | x |
| 2010-06-30 | $-0.01 | $0.00 | x |
| 2011-06-30 | $-0.02 | $0.00 | x |
| 2012-06-30 | $-0.02 | $0.00 | x |
| 2013-06-30 | $-0.02 | $0.00 | x |
| 2014-06-30 | $-0.02 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Molecular Pharmacology (USA) Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-27.02%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -243.15% | 0.00% | 0.00x | 1.12x | $-50.38K |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-358.83K |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-434.53K |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $34.78K |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $31.47K |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $74.81K |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $28.60K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.51K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $106.36K |
Industry Comparison
This section compares Molecular Pharmacology (USA) Ltd's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $36,677,338
- Average return on equity (ROE) among peers: -64.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Molecular Pharmacology (USA) Ltd (MLPH) | $-2.10 Million | -243.15% | N/A | $3.73 |
| Artius II Acquisition Inc. Class A Ordinary Shares (AACB) | $-60.27K | 0.00% | 0.00x | $198.37 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $205.28 Million |
| Ares Acquisition Corporation II (AACT-UN) | $931.34 Million | 0.00% | 0.08x | $399.77 Million |
| AA Mission Acquisition Corp. (AAM-UN) | $-559.90 Million | 0.00% | 0.00x | $349.76 Million |
| Global Acquisitions Corporation (AASP) | $3.80 Million | -5.26% | 0.34x | $15.42 Million |
| ABV Consulting Inc (ABVN) | $8.75K | -623.31% | 2.50x | $461.96K |
| Atlantic Coastal Acquisition Corp II (ACAB) | $-8.52 Million | 0.00% | 0.00x | $2.44 Million |
| Annabidiol Corp (ACBD) | $-501.57K | 0.00% | 0.00x | $13.62K |
| ACRO Biomedical Co Ltd (ACBM) | $685.87K | -17.12% | 0.46x | $30.04K |
| Huaizhong Health Group Inc (ADAD) | $-19.47K | 0.00% | 0.00x | $3.15K |